Excaliard Pharmaceuticals is a San Diego-based biopharmaceutical company developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The Company recently completed three Phase 2 trials with its lead product, EXC 001. Results from all three studies have demonstrated statistically significant reductions in scar severity compared to placebo. EXC 001 was also well tolerated with no important drug related adverse effects observed. Currently, there are no FDA-approved products to reduce scar severity, and the Company believes that EXC 001 is well positioned to be at the forefront of this multi-billion dollar market opportunity.

Key Features

Business Development

Excaliard has successfully completed three Phase 2 trials in elective surgical procedures. These studies demonstrated the efficacy and safety of EXC 001 in elective revision surgery of scars resulting from prior breast surgery, in fine line scars in elective abdominoplasty surgery and in a biomarker study of abdominal scarring.

For information about business development opportunities at Excaliard Pharmaceuticals please contact business.development@excaliard.com